TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.16 Million EUR | -71.46% |
| 2022 | 4.08 Million EUR | 67.46% |
| 2021 | 2.44 Million EUR | 3436.23% |
| 2020 | 69 Thousand EUR | -39.47% |
| 2019 | 114 Thousand EUR | -97.62% |
| 2018 | 4.78 Million EUR | 83.76% |
| 2017 | 2.6 Million EUR | -11.42% |
| 2016 | 2.94 Million EUR | -66.88% |
| 2015 | 8.88 Million EUR | 40.53% |
| 2014 | 6.31 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 118 Thousand EUR | 0.0% |
| 2023 FY | 1.16 Million EUR | -71.46% |
| 2023 Q4 | 1.16 Million EUR | 6.0% |
| 2023 Q3 | 1.1 Million EUR | -52.79% |
| 2023 Q1 | 2.21 Million EUR | -45.86% |
| 2023 Q2 | 2.33 Million EUR | 5.33% |
| 2022 Q3 | 3.97 Million EUR | 112.17% |
| 2022 Q1 | 1.7 Million EUR | -30.04% |
| 2022 Q2 | 1.87 Million EUR | 9.72% |
| 2022 FY | 4.08 Million EUR | 67.46% |
| 2022 Q4 | 4.08 Million EUR | 2.82% |
| 2021 Q2 | 45 Thousand EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q4 | 2.44 Million EUR | 0.87% |
| 2021 FY | 2.44 Million EUR | 3436.23% |
| 2021 Q3 | 2.41 Million EUR | 5275.56% |
| 2020 Q4 | 69 Thousand EUR | -88.6% |
| 2020 FY | 69 Thousand EUR | -39.47% |
| 2020 Q2 | 92 Thousand EUR | -9.8% |
| 2020 Q1 | 102 Thousand EUR | -10.53% |
| 2020 Q3 | 605 Thousand EUR | 557.61% |
| 2019 Q4 | 114 Thousand EUR | 35.71% |
| 2019 FY | 114 Thousand EUR | -97.62% |
| 2019 Q3 | 84 Thousand EUR | -37.78% |
| 2019 Q2 | 135 Thousand EUR | 33.66% |
| 2019 Q1 | 101 Thousand EUR | -97.89% |
| 2018 Q3 | 87 Thousand EUR | -96.87% |
| 2018 Q4 | 4.78 Million EUR | 5402.3% |
| 2018 FY | 4.78 Million EUR | 83.76% |
| 2018 Q1 | 2.78 Million EUR | 6.79% |
| 2018 Q2 | 2.78 Million EUR | 0.0% |
| 2017 Q3 | 2.6 Million EUR | 66.45% |
| 2017 FY | 2.6 Million EUR | -11.42% |
| 2017 Q1 | 1.56 Million EUR | -46.79% |
| 2017 Q2 | 1.56 Million EUR | 0.0% |
| 2017 Q4 | 2.6 Million EUR | 0.0% |
| 2016 Q1 | 11.08 Million EUR | 24.79% |
| 2016 Q3 | 2.94 Million EUR | -73.46% |
| 2016 Q4 | 2.94 Million EUR | 0.0% |
| 2016 FY | 2.94 Million EUR | -66.88% |
| 2016 Q2 | 11.08 Million EUR | 0.0% |
| 2015 FY | 8.88 Million EUR | 40.53% |
| 2015 Q4 | 8.88 Million EUR | 0.0% |
| 2015 Q3 | 8.88 Million EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2014 FY | 6.31 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 65.605% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 97.898% |
| Adocia SA | 13.08 Million EUR | 91.091% |
| Aelis Farma SA | 4.03 Million EUR | 71.124% |
| Biophytis S.A. | 8.27 Million EUR | 85.901% |
| Advicenne S.A. | 17.42 Million EUR | 93.308% |
| genOway Société anonyme | 7.23 Million EUR | 83.88% |
| IntegraGen SA | 1.12 Million EUR | -3.669% |
| Medesis Pharma S.A. | 1.2 Million EUR | 2.833% |
| Neovacs S.A. | 650 Thousand EUR | -79.385% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1775.382% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 73.235% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 57.082% |
| Sensorion SA | 2.86 Million EUR | 59.356% |
| Theranexus Société Anonyme | 3.64 Million EUR | 67.994% |
| Valbiotis SA | 6.87 Million EUR | 83.047% |
| TheraVet SA | 1.15 Million EUR | -0.529% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 87.042% |
| argenx SE | 18.1 Million EUR | 93.56% |
| BioSenic S.A. | 28.16 Million EUR | 95.86% |
| Celyad Oncology SA | 902 Thousand EUR | -29.268% |
| DBV Technologies S.A. | 13.01 Million USD | 91.044% |
| Galapagos NV | 9.59 Million EUR | 87.849% |
| Genfit S.A. | 70.17 Million EUR | 98.339% |
| GeNeuro SA | 7.73 Million EUR | 84.931% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 77.975% |
| Innate Pharma S.A. | 39.89 Million EUR | 97.077% |
| Inventiva S.A. | 37.4 Million EUR | 96.883% |
| MaaT Pharma SA | 14.07 Million EUR | 91.716% |
| MedinCell S.A. | 58.96 Million EUR | 98.022% |
| Nanobiotix S.A. | 50.56 Million EUR | 97.694% |
| Onward Medical N.V. | 16.87 Million EUR | 93.09% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 91.481% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 97.454% |
| Oxurion NV | 12.33 Million EUR | 90.546% |
| Pharming Group N.V. | 155.29 Million EUR | 99.249% |
| Poxel S.A. | 46.9 Million EUR | 97.514% |
| GenSight Biologics S.A. | 18.42 Million EUR | 93.673% |
| Transgene SA | 1.25 Million EUR | 7.239% |
| Financière de Tubize SA | 79.2 Million EUR | 98.528% |
| UCB SA | 3.03 Billion EUR | 99.962% |
| Valneva SE | 208.81 Million EUR | 99.442% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -2968.421% |